Accreditation Information

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing (ANCC)

This activity is designated for 1.0 contact hour.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Upon completion of a CNE request form, statements of credit for nurses will be issued within 30 business days.

ONCC/ILNA Certification Information

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. Certification qualifications will be provided to participants at the live meeting.

ONCC/ILNA Disclaimer: ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.

Needs Statement

The introduction of immune checkpoint inhibition has dramatically improved the care of patients with many advanced malignancies and will continue to transform the cancer treatment landscape. Because inhibiting these pathways stimulate the immune system, the adverse events experienced differ from those typically seen with chemotherapy. In order to fully utilize these novel therapies to their greatest potential, all members of the oncology healthcare team must become familiar with immune-mediated adverse events to ensure optimal patient outcomes. As front-line care givers, oncology nurses are optimally positioned to quickly identify such adverse events and employ appropriate management strategies. The objective of this educational inititative is to provide oncology nurses and nurse practitioners evidence-based information on the latest developments in the use of cancer immunotherapy and effective management of associated immuned-mediated adverse events.

 

Objectives

  • Outline the key principles of the human immune response and the mechanisms by which immunotherapies target various solid tumor types.
  • Discuss emerging research on the clinical efficacy and safety of cancer immunotherapies and identify their place in the treatment algorithm of solid tumors.
  • Evaluate the signs and symptoms of immune-mediated adverse events associated with checkpoint inhibitors and preventative strategies members of the healthcare team can take to mitigate and manage imAEs.
  • Explore challenging cases regarding immunotherapies, including early recognition and proper management of imAEs.

 

Target Audience

This activity is designed to meet the educational needs of oncology nurses and nurse practitioners attending local ONS Chapter Meetings across the U.S.

Faculty Disclosure

Planner and Faculty Disclosures

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planner: 
Vanessa Carranza, PharmD - has no relevant financial relationships to disclose in relation to the content of this activity.

Authors/Presenters:

Stephanie Andrews, MS, ANP-BC - has no relevant financial relationships to disclose in relation to the content of this activity.

Grace Cherry, NP - has disclosed that she is a member of the speakers’ bureaus for Merck, Genentech, and Novartis.

RuthAnn Gordon, MSN, FNP-BC, RN, OCN  - has no relevant financial relationships to disclose in relation to the content of this activity.

Victoria Sherry, DNP, CRNP, ANP-BC, AOCNP - has no relevant financial relationships to disclose in relation to the content of this activity.

 

Peer Reviewer:

Grace Cherry, NP - has disclosed that she is a member of the speakers’ bureaus for Merck, Genentech, and Novartis.